Viewing Study NCT05035732


Ignite Creation Date: 2025-12-24 @ 9:23 PM
Ignite Modification Date: 2026-01-01 @ 8:42 AM
Study NCT ID: NCT05035732
Status: WITHDRAWN
Last Update Posted: 2024-01-18
First Post: 2021-08-24
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Prospective Pilot Study for the Evaluation of 18F- Fluciclovine PET/MRI in Radio-recurrent Prostate Cancer (RRPC-PET/MRI Study)
Sponsor: M.D. Anderson Cancer Center
Organization:

Study Overview

Official Title: A Prospective Pilot Study for the Evaluation of 18F- Fluciclovine PET/MRI in Radio-recurrent Prostate Cancer (RRPC-PET/MRI Study)
Status: WITHDRAWN
Status Verified Date: 2024-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: 0 participant accrual
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To perform both PET scans and MRIs in the same setting using a simultaneous PET/MRI scanner.
Detailed Description: Primary Objective:

--To compare the diagnostic performance of 18F- Fluciclovine pelvic PET/MRI to that of pelvic mpMRI and to determine whether 18F- Fluciclovine pelvic PET/MRI is more accurate than a pelvic mpMRI in detecting pelvic RRPC in men with biochemical recurrence with histopathology as reference standard.

Secondary Objective:

--To study inter-reader reliability of 18F- Fluciclovine pelvic PET/MRI and pelvic mpMRI among the readers.

Exploratory Objective:

--To study correlation between SUVmax and ADCmean in the pelvic RRPC.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
NCI-2021-09407 OTHER NCI-CTRP Clinical Trials Registry View